GlaxoSmithKline PLC (NYSE:GSK) has earned a consensus rating of “Hold” from the twenty-one ratings firms that are presently covering the stock. Two analysts have rated the stock with a sell recommendation, eight have given a hold recommendation and eleven have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $48.25.

GSK has been the subject of several recent analyst reports. Bank of America Corp. reiterated a “buy” rating and issued a $50.00 target price on shares of GlaxoSmithKline PLC in a report on Tuesday, September 20th. Citigroup Inc. reiterated a “buy” rating on shares of GlaxoSmithKline PLC in a report on Wednesday, August 10th. BNP Paribas cut shares of GlaxoSmithKline PLC from a “neutral” rating to an “underperform” rating in a report on Tuesday, September 13th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of GlaxoSmithKline PLC in a report on Friday, September 16th. Finally, Beaufort Securities reiterated a “buy” rating on shares of GlaxoSmithKline PLC in a report on Tuesday, August 2nd.

In other GlaxoSmithKline PLC news, major shareholder Plc Glaxosmithkline bought 66,500 shares of GlaxoSmithKline PLC stock in a transaction on Monday, October 24th. The stock was purchased at an average cost of $14.00 per share, for a total transaction of $931,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 10.00% of the stock is currently owned by company insiders.

Hedge funds have recently bought and sold shares of the stock. First Republic Investment Management Inc. boosted its stake in GlaxoSmithKline PLC by 30.7% in the first quarter. First Republic Investment Management Inc. now owns 39,201 shares of the pharmaceutical company’s stock worth $1,590,000 after buying an additional 9,208 shares during the period. Cullinan Associates Inc. boosted its stake in GlaxoSmithKline PLC by 6.0% in the first quarter. Cullinan Associates Inc. now owns 10,571 shares of the pharmaceutical company’s stock worth $429,000 after buying an additional 600 shares during the period. BNP Paribas Arbitrage SA boosted its stake in GlaxoSmithKline PLC by 2.2% in the second quarter. BNP Paribas Arbitrage SA now owns 142,234 shares of the pharmaceutical company’s stock worth $6,164,000 after buying an additional 3,071 shares during the period. Iowa State Bank boosted its stake in GlaxoSmithKline PLC by 4.6% in the second quarter. Iowa State Bank now owns 42,406 shares of the pharmaceutical company’s stock worth $1,838,000 after buying an additional 1,855 shares during the period. Finally, Fulton Bank N.A. boosted its stake in GlaxoSmithKline PLC by 2.9% in the second quarter. Fulton Bank N.A. now owns 96,034 shares of the pharmaceutical company’s stock worth $4,162,000 after buying an additional 2,700 shares during the period. Hedge funds and other institutional investors own 8.67% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was first reported by Daily Political and is owned by of Daily Political. If you are viewing this news story on another site, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The legal version of this news story can be viewed at http://www.dailypolitical.com/2016/11/29/glaxosmithkline-plc-gsk-receives-consensus-recommendation-of-hold-from-analysts.html.

GlaxoSmithKline PLC (NYSE:GSK) traded down 0.03% during midday trading on Tuesday, hitting $38.28. 3,040,322 shares of the stock traded hands. The company has a 50-day moving average price of $39.97 and a 200-day moving average price of $42.36. GlaxoSmithKline PLC has a 1-year low of $37.65 and a 1-year high of $45.58. The firm has a market cap of $93.14 billion, a P/E ratio of 251.84 and a beta of 0.93.

The firm also recently announced a dividend, which will be paid on Thursday, January 12th. Shareholders of record on Friday, November 4th will be paid a $0.459 dividend. The ex-dividend date is Wednesday, November 2nd. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is presently 1,533.33%.

About GlaxoSmithKline PLC

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

5 Day Chart for NYSE:GSK

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.